Advertisement

Table of Contents

March 29, 2018; 131 (13)

BLOOD COMMENTARIES

BLOOD SPOTLIGHT

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

  • Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
    Anne-Ségolène Cottereau, Annibale Versari, Annika Loft, Olivier Casasnovas, Monica Bellei, Romain Ricci, Stéphane Bardet, Antonio Castagnoli, Pauline Brice, John Raemaekers, Bénédicte Deau, Catherine Fortpied, Tiana Raveloarivahy, Emelie Van Zele, Loic Chartier, Thierry Vander Borght, Massimo Federico, Martin Hutchings, Umberto Ricardi, Marc Andre and Michel Meignan
  • Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation
    Heike Pfeifer, Katharina Raum, Sandra Markovic, Verena Nowak, Stephanie Fey, Julia Obländer, Jovita Pressler, Verena Böhm, Monika Brüggemann, Lydia Wunderle, Andreas Hüttmann, Ralph Wäsch, Joachim Beck, Matthias Stelljes, Andreas Viardot, Fabian Lang, Dieter Hoelzer, Wolf-Karsten Hofmann, Hubert Serve, Christel Weiss, Nicola Goekbuget, Oliver G. Ottmann and Daniel Nowak

TRANSPLANTATION

LETTERS TO BLOOD

BLOOD WORK